Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 19/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 15/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 15/20 | 1.00 |
| ▸ | MTOR | P42345 | 15/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 14/20 | 1.00 |
| ▸ | RPTOR | Q8N122 | 1/20 | 1.00 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 1.00 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.72 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.72 |
| ▸ | STK10 | O94804 | 1/20 | 0.72 |
| ▸ | PAK4 | O96013 | 1/20 | 0.72 |
| ▸ | ABL1 | P00519 | 1/20 | 0.72 |
| ▸ | EGFR | P00533 | 1/20 | 0.72 |
| ▸ | FGR | P09769 | 1/20 | 0.72 |
| ▸ | FER | P16591 | 1/20 | 0.72 |
| ▸ | PRKCA | P17252 | 1/20 | 0.72 |
| ▸ | JAK1 | P23458 | 1/20 | 0.72 |
| ▸ | TEC | P42680 | 1/20 | 0.72 |
| ▸ | SYK | P43405 | 1/20 | 0.72 |
| ▸ | PRKDC | P78527 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29367908 | 1.00 | PIK3CA (1.00) | PIK3CAPIK3CBPIK3CDMTORPIK3CG | |
| SCHEMBL1181061 | 0.92 | PIK3CA (0.85) | PIK3CAPIK3CBPIK3CDMTORPIK3CG | |
| SCHEMBL1180461 | 0.91 | PIK3CA (0.83) | PIK3CAPIK3CBPIK3CDMTORPIK3CG | |
| SCHEMBL1181601 | 0.91 | PIK3CA (0.83) | PIK3CAPIK3CBPIK3CDMTORPIK3CG | |
| SCHEMBL1181551 | 0.90 | PIK3CA (0.81) | PIK3CAPIK3CBPIK3CDMTORPIK3CG | |
| SCHEMBL1181644 | 0.89 | PIK3CA (0.80) | PIK3CAPIK3CBPIK3CDMTORPIK3CG | |
| SCHEMBL1181727 | 0.88 | PIK3CA (0.79) | PIK3CAPIK3CBPIK3CDMTORPIK3CG | |
| SCHEMBL1181030 | 0.88 | PIK3CA (0.84) | PIK3CAPIK3CBPIK3CDMTORPIK3CG | |
| SCHEMBL4440311 | 0.88 | PIK3CA (0.78) | PIK3CAPIK3CBPIK3CDMTORPIK3CG | |
| SCHEMBL1178409 | 0.87 | PIK3CA (0.77) | PIK3CAPIK3CBPIK3CDMTORPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024015855-A1 | COMBINATION THERAPY COMPRISING GSPT1-DIRECTED MOLECULAR GLUE DEGRADERS AND PI3K/AKT/mTOR PATHWAY INHIBITORS | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | claimed |
| EP-2518074-B1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | HOFFMANN LA ROCHE (CH) | 2015-07-22 | — | — | EP | claimed |
| US-20130129820-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-05-23 | — | — | US | claimed |
| US-8383620-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-02-26 | — | — | US | claimed |
| EP-2518074-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | F. Hoffmann-La Roche AG (CH) | 2012-10-31 | — | — | EP | claimed |
| US-20110097349-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-04-28 | — | — | US | claimed |
| US-7888352-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIRAMED LIMITED (GB) | 2011-02-15 | — | — | US | claimed |
| EP-2114949-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2009-11-11 | — | — | EP | claimed |
| US-20080242665-A1 | 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-02 | — | — | US | claimed |
| WO-2008070740-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | claimed |
| US-20250025469-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2025-01-23 | — | — | US | disclosed |
| US-20240325398-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2024-10-03 | — | — | US | disclosed |
| US-20240293415-A1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. | 2024-09-05 | — | — | US | disclosed |
| US-11944631-B2 | Combination therapies | INFINITY PHARMACEUTICALS, INC. (US) | 2024-04-02 | — | — | US | disclosed |
| WO-2024015855-A1 | COMBINATION THERAPY COMPRISING GSPT1-DIRECTED MOLECULAR GLUE DEGRADERS AND PI3K/AKT/mTOR PATHWAY INHIBITORS | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20080242665-A1 | 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-20080242665-A1 | 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-20080242665-A1 | 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-02 | — | — | US | disclosed |
| WO-2008070740-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008070740-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025469-A1 | COMBINATION THERAPIES | BCL2, BAK1, BCL3 | PIK3CA 24/4885PIK3CB 23/4885PIK3CD 29/4885 |
| US-11944631-B2 | Combination therapies | BCL2, BAK1, BCL3 | PIK3CA 24/4885PIK3CB 23/4885PIK3CD 29/4885 |
| US-20110097349-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, AKT3, PI4KA | PIK3CA 1/4885PIK3CB 15/4885PIK3CD 5/4885 |
| US-20240293415-A1 | COMBINATION THERAPIES | FLT3, TLR3, BTK | PIK3CA 100/4885PIK3CB 181/4885PIK3CD 161/4885 |
| US-20080242665-A1 | 1-(4-((2-(2-aminopyrimidin-5-yl)-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticarcinogenic agent; | PI4KA, DMPK, PDPK1 | PIK3CA 9/4885PIK3CB 48/4885PIK3CD 11/4885 |
| US-20240325398-A1 | COMBINATION THERAPIES | HDAC1, HDAC4, HDAC2 | PIK3CA 18/4885PIK3CB 43/4885PIK3CD 23/4885 |
| US-20130129820-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, AKT3, PI4KA | PIK3CA 1/4885PIK3CB 15/4885PIK3CD 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.